Xiangyu Long,* Bintao Hu,* Shiqing Zhu, Yue Wu, Tao Wang

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Tao Wang, Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China, Email tjhwt@126.com

Abstract: N6-methyladenosine (m6A) is the most common modification on mammalian mRNA and has gained considerable attention in recent years as a key regulator of gene expression. RBM15 is an important component of the methyltransferase complex. Although its functions are increasingly being recognized, a comprehensive overview of its critical roles in cancer regulation and potential therapeutic relevance is still lacking. This review aims to summarize recent advances in RBM15 by outlining its physiological functions in normal organisms, detailing its biological roles in tumor regulation and discussing its potential clinical applications. This work highlights its potential as a therapeutic target in oncology.

Keywords: RBM15, m6A modification, tumor, therapeutic targets